// App-Quantinova.ai

T1077 2016 AHA : The Pro-Hypertrophic High Molecular Weight Fgf2 Activates Ampk or Erk by Engaging, Respectively, Fgfr1-Independent or Fgfr1-Dependent Pathways

Researchers

Presenter

  • Barbara E Nickel

Principal Investigators

  • Robert R Fandrich

  • Peter A Cattini

  • Elissavet Kardami

Medical Centers

  • St.Boniface Hosp Albrechtsen Res Ctr, Winnipeg, MB, Canada

  • Univ of Manitoba, Winnipeg, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Cardiovascular (CVS)

Disease

  • Hypertrophic cardiomyopathy

Biomarkers

  • Activin A

  • AMP-activated protein kinase

  • Basic fibroblast growth factor

  • Nucleoside diphosphate kinase A

  • Extracellular signal-regulated kinase

Drug/Treatment

  • Doxorubicin

  • SU-5402

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved